Prostatype Genomics AB (FRA:PGO) ROCE % : -165.33% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Prostatype Genomics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Prostatype Genomics AB's annualized ROCE % for the quarter that ended in Jun. 2023 was -165.33%.

Prostatype Genomics AB ROCE % Historical Data

The historical data trend for Prostatype Genomics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB ROCE % Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

ROCE %

-58.08

-50.25

-60.67

-86.99

-153.97

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial											-103.29	-104.78	-135.97	-165.33	-

Prostatype Genomics AB ROCE % Calculation

Prostatype Genomics AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.566	/	( ( (2.815 - 0.394)	+	(4.4 - 2.189) )	/ 2 )
	=	-3.566	/	( (2.421	+	2.211)	/ 2 )
	=	-3.566	/	2.316
	=	-153.97 %

Prostatype Genomics AB's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-3.448	/	( ( (2.115 - 0.447)	+	(2.979 - 0.476) )	/ 2 )
	=	-3.448	/	( ( 1.668	+	2.503 )	/ 2 )
	=	-3.448	/	2.0855
	=	-165.33 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Prostatype Genomics AB (FRA:PGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Prostatype Genomics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (FRA:PGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (FRA:PGO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PROGEN:Sweden

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (FRA:PGO) Headlines

No Headlines